Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for prostate cancer
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on prostate cancer or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on prostate cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via firstname.lastname@example.org
Evaluating the potential benefit of reduced planning target volume margins for low and intermediate risk patients with prostatecancer using real-time electromagnetic tracking The aim of this study is to quantify and describe the feasibility, clinical outcomes, and patient-reported outcomes of reduced planning target volume (PTV) margins for prostatecancer treatment using real-time, continuous, intrafraction monitoring with implanted radiation frequency transponder beacons.For this prospective (...) (0.05 mm and 0.06 mm, respectively). At 6 months, patients demonstrated a smaller change in Expanded ProstateCancer Index Composite scores than the ProtecT comparator group (decreased short-term morbidity). However, in the Bowel and Urinary domains at 12 and 24 months, there was no significant difference.Our data confirm and support that the use of Calypso tracking with intensity modulated radiation therapy reliably provides minimal disruption to daily treatments and overall time of treatment
Making Sense of the Statin-ProstateCancer Relationship: Is It Time for a Randomized Controlled Trial? 28753767 2018 07 10 2018 12 02 2405-4569 3 2-3 2017 04 European urology focus Eur Urol Focus Making Sense of the Statin-ProstateCancer Relationship: Is It Time for a Randomized Controlled Trial? 221-222 S2405-4569(16)30068-2 10.1016/j.euf.2016.06.008 Hamilton Robert J RJ Division of Urology, Departments of Surgical Oncology, Princess Margaret Cancer Centre, University Health Network (...) and the University of Toronto, Toronto, Canada. Electronic address: email@example.com. eng Editorial Comment 2016 06 23 Netherlands Eur Urol Focus 101665661 2405-4569 0 Hydroxymethylglutaryl-CoA Reductase Inhibitors EC 220.127.116.11 Prostate-Specific Antigen IM Eur Urol Focus. 2017 Apr;3(2-3):212-220 28753762 Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors Male Prostate-Specific Antigen ProstaticNeoplasms 2016 05 30 2016 06 13 2017 7 30 6 0 2018 7 11 6 0 2017 7 30 6 0 ppublish 28753767 S2405-4569(16)30068-2
Contemporary Radiation Treatment of ProstateCancer in Africa: A Ghanaian Experience Purpose Data on prostatecancer (PCa) treatment in Africa remains under-reported. We present a review of the management of PCa at the cancer center of the largest tertiary referral facility in Ghana, with emphasis on curative treatment. Methods We retrospectively reviewed data on 1,074 patients seen at the National Center for Radiotherapy and Nuclear Medicine from 2003 to 2016. Patient and disease (...) with localized disease received curative radiotherapy. The 5-year overall survival for the curative cohort was 96% (interquartile range, 93% to 98%). The 5-year bDFS rates for low-, intermediate-, and high-risk groups were 95%, 70%, and 48%, respectively. Both Gleason score and pretreatment prostate-specific antigen were significant predictors for bDFS in multivariable analysis. Conclusion We show that the majority of patients with PCa have locally advanced disease at the time of presentation
Systems pharmacology using mass spectrometry identifies critical response nodes in prostatecancer In the United States alone one in five newly diagnosed cancers in men are prostatecarcinomas (PCa). Androgen receptor (AR) status and the PI3K-AKT-mTOR signal transduction pathway are critical in PCa. After initial response to single drugs targeting these pathways resistance often emerges, indicating the need for combination therapy. Here, we address the question of efficacy of drug combinations (...) pathways in PCa cells. Some of the upregulated proteins such as 14-3-3 proteins and KLK2 may be useful early markers of adaptive response and indicate potential resistance pathways targetable as part of combination therapy to overcome drug resistance. The potential of 14-3-3ζ (YWHAZ) as a target is underscored by the independent observation, based on cancer genomics of surgical specimens, that its DNA copy number and transcript levels tend to increase with PCa disease progression. The combination
. Median follow-up was 11.2 years. The 10-year OS estimates were 87% with ADT (expected 50%) and 86% with ADT + MP (hazard ratio, 1.06; 95% CI, 0.79 to 1.43). The 10-year estimate for disease-free survival was 72% for both arms. Prostatecancer was the cause of death in 18% of patients in the ADT arm and 22% in the ADT + MP arm. More patients in the MP arm died of other cancers (36% v 18% in ADT alone arm). Conclusion MP did not improve OS and increased deaths from other malignancies. The DFS and 10 (...) . Methods Eligible patients had cT1-3N0 prostatecancer with one or more high-risk factors after radical prostatectomy (Gleason score [GS] ≥ 8; pT3b, pT4, or pN+ disease; GS 7 and positive margins; or preoperative prostate-specific antigen [PSA] > 15 ng/mL, biopsy GS score > 7, or PSA > 10 ng/mL plus biopsy GS > 6. Patients with PSA ≤ 0.2 ng/mL after radical prostatectomy were stratified by pT/N stage, GS, and adjuvant radiation plan and randomly assigned to ADT (bicalutamide and goserelin for 2 years
Efferocytosis and prostatecancer skeletal metastasis: implications for intervention 30035182 2018 11 14 2331-4737 5 5-6 2018 May Oncoscience Oncoscience Efferocytosis and prostatecancer skeletal metastasis: implications for intervention. 174-176 10.18632/oncoscience.440 Roca Hernan H Department of Periodontics and Oral Medicine, University of Michigan, School of Dentistry, Ann Arbor, MI 48109-1078, USA. McCauley Laurie K LK Department of Periodontics and Oral Medicine, University of Michigan (...) , School of Dentistry, Ann Arbor, MI 48109-1078, USA. eng P01 CA093900 CA NCI NIH HHS United States R01 DK053904 DK NIDDK NIH HHS United States Editorial 2018 06 29 United States Oncoscience 101636666 2331-4737 efferocytosis inflammation macrophage prostatecancer skeletal metastasis CONFLICTS OF INTEREST The authors declare no conflicts of interest. 2018 05 02 2018 05 18 2018 7 24 6 0 2018 7 24 6 0 2018 7 24 6 1 epublish 30035182 10.18632/oncoscience.440 440 PMC6049312 Cancer Cell. 2016 Apr 11;29(4
Enzalutamide in Men with Nonmetastatic, Castration-Resistant ProstateCancer. Men with nonmetastatic, castration-resistant prostatecancer and a rapidly rising prostate-specific antigen (PSA) level are at high risk for metastasis. We hypothesized that enzalutamide, which prolongs overall survival among patients with metastatic, castration-resistant prostatecancer, would delay metastasis in men with nonmetastatic, castration-resistant prostatecancer and a rapidly rising PSA level.In (...) this double-blind, phase 3 trial, we randomly assigned, in a 2:1 ratio, men with nonmetastatic, castration-resistant prostatecancer and a PSA doubling time of 10 months or less who were continuing androgen-deprivation therapy to receive enzalutamide (at a dose of 160 mg) or placebo once daily. The primary end point was metastasis-free survival (defined as the time from randomization to radiographic progression or as the time to death without radiographic progression).A total of 1401 patients (median PSA
Salvage reirradiation for local failure of prostatecancer after curative radiation therapy: Association of rectal toxicity with dose distribution and normal-tissue complication probability models This study aimed to assess the impact of radiation dose on rectal toxicity after salvage external beam radiation therapy (EBRT) with or without a brachytherapy boost for exclusive local failures after the primary EBRT for prostate cancer.Fourteen patients with no severe residual late toxicity after (...) primary EBRT ± brachytherapy were reirradiated after a median time interval of 6.1 years. The median normalized total dose in 2 Gy fractions (NTD2Gy, α/β ratio = 1.5 Gy for prostatecancer cells) was 74 Gy at primary EBRT and 85.1 Gy at reirradiation. Rectal dose-volume histograms (converted to NTD2Gy_alpha/beta = 3 Gy) and the corresponding normal-tissue complication probability (NTCP) values for gastrointestinal (GI) toxicity were evaluated for 2 groups: High GI toxicity (grade ≥3) and low GI
Comparative Toxicities and Cost of Intensity-Modulated Radiotherapy, Proton Radiation, and Stereotactic Body Radiotherapy Among Younger Men With ProstateCancer. Purpose To compare the toxicities and cost of proton radiation and stereotactic body radiotherapy (SBRT) with intensity-modulated radiotherapy (IMRT) for prostatecancer among men younger than 65 years of age with private insurance. Methods Using the MarketScan Commercial Claims and Encounters database, we identified men who received (...) radiation for prostatecancer between 2008 and 2015. Patients undergoing proton therapy and SBRT were propensity score-matched to IMRT patients on the basis of clinical and sociodemographic factors. Proportional hazards models compared the cumulative incidence of urinary, bowel, and erectile dysfunction toxicities by treatment. Cost from a payer's perspective was calculated from claims and adjusted to 2015 dollars. Results A total of 693 proton therapy patients were matched to 3,465 IMRT patients
(with prednisone or prednisolone) to ADT. LATITUDE and STAMPEDE favored abiraterone (HR, 0.62; 95% CI, 0.51 to 0.76; n = 1,199 and HR, 0.63; 95% CI, 0.52 to 0.76; n = 1,917, respectively). Recommendations ADT plus docetaxel or abiraterone in newly diagnosed metastatic non-castrate prostatecancer offers a survival benefit as compared with ADT alone. The strongest evidence of benefit with docetaxel is in men with de novo high-volume (CHAARTED criteria) metastatic disease. Similar survival benefits are seen (...) Optimizing Anticancer Therapy in Metastatic Non-Castrate ProstateCancer: American Society of Clinical Oncology Clinical Practice Guideline Purpose This clinical practice guideline addresses abiraterone or docetaxel with androgen-deprivation therapy (ADT) for metastatic prostatecancer that has not been treated (or has been minimally treated) with testosterone-lowering agents. Methods Standard therapy for newly diagnosed metastatic prostatecancer has been ADT alone. Three studies have compared
Cancer Treatmentâ€“Induced Bone Loss in Women With Breast Cancer and Men With ProstateCancerCancer and cancer therapies can have a negative impact on bone health. Because cancer is a common diagnosis, survivorship concerns for osteoporosis and fragility fractures are an important component of care. This review addresses management of bone health in nonmetastatic cancer survivorship with a focus on breast cancer and prostatecancer.
Survivin polymorphisms and susceptibility to prostatecancer: A genetic association study and an in silico analysis Survivin is a member of the apoptosis inhibitor protein family and its polymorphisms may lead to susceptibility to cancer. The aim of this study was to investigate the possible association of c.-31G>C (rs9904341), c.454G>A (rs2071214), c.*148T>C (rs2239680) and c.*571T>C (rs1042489) polymorphisms of survivin gene with prostatecancer risk and provide some justification using (...) in silico analysis. The 157 men with prostatecancer and 145 healthy controls were included in a case-control study. The studied polymorphisms were genotyped using PCR-RFLP method. An in silico approach was employed to show the possible effects of the polymorphisms on the survivin gene function. The study revealed that there are significant associations between c.-31CC genotype (OR= 2.29, 95 % CI= 1.20-4.37, p= 0.012), c.-31C allele (OR= 1.62, 95 % CI= 1.17-2.26, p= 0.004), c.454AG genotype (OR= 2.03
Development of sarcosine quantification in urine based on enzyme-coupled colorimetric method for prostatecancer diagnosis An enzyme-coupled colorimetric assay for quantification of urinary sarcosine was developed. The proposed method is a specific reaction based on hydrogen peroxide (H2O2) formation via sarcosine oxidase (SOX). The liberated H2O2 reacts with Amplex Red in the presence of horseradish peroxidase (HRP) to produce the red-fluorescent oxidation product, resorufin, which can (...) amino acids. The determination of sarcosine in human urine displayed high accuracy and good reproducibility. This method is promising to differentiate prostatecancer patients from healthy subjects according to urinary sarcosine level. Altogether, this study provides a rapid, simple and specific tool to determine urinary sarcosine which could be useful for prostatecancer diagnosis.
Use of Conservative Management for Low-Risk ProstateCancer in the Veterans Affairs Integrated Health Care System From 2005-2015 29800017 2018 07 10 2018 12 02 1538-3598 319 21 2018 06 05 JAMA JAMA Use of Conservative Management for Low-Risk ProstateCancer in the Veterans Affairs Integrated Health Care System From 2005-2015. 2231-2233 10.1001/jama.2018.5616 Loeb Stacy S Manhattan Veterans Affairs Medical Center, New York, New York. Byrne Nataliya N Department of Urology, New York University (...) Conservative Treatment statistics & numerical data trends Delivery of Health Care, Integrated Humans Logistic Models Male Middle Aged Multivariate Analysis Prostate-Specific Antigen blood ProstaticNeoplasms therapy Risk Factors United States United States Department of Veterans Affairs Veterans Watchful Waiting 2018 5 26 6 0 2018 7 11 6 0 2018 5 26 6 0 ppublish 29800017 2681802 10.1001/jama.2018.5616 PMC6134433 JAMA Oncol. 2017 Oct 1;3(10):1393-1398 27768168 BJU Int. 2017 Jul;120(1):32-39 27611479 J Clin
Screening for ProstateCancer: US Preventive Services Task Force Recommendation Statement. In the United States, the lifetime risk of being diagnosed with prostatecancer is approximately 13%, and the lifetime risk of dying of prostatecancer is 2.5%. The median age of death from prostatecancer is 80 years. Many men with prostatecancer never experience symptoms and, without screening, would never know they have the disease. African American men and men with a family history of prostatecancer (...) have an increased risk of prostatecancer compared with other men.To update the 2012 US Preventive Services Task Force (USPSTF) recommendation on prostate-specific antigen (PSA)-based screening for prostate cancer.The USPSTF reviewed the evidence on the benefits and harms of PSA-based screening for prostatecancer and subsequent treatment of screen-detected prostatecancer. The USPSTF also commissioned a review of existing decision analysis models and the overdiagnosis rate of PSA-based screening
Comparison of Quantitative Apparent Diffusion Coefficient Parameters with Prostate Imaging Reporting and Data System V2 Assessment for Detection of Clinically Significant Peripheral Zone ProstateCancer To compare diagnostic performance of PI-RADSv2 with ADC parameters to identify clinically significant prostatecancer (csPC) and to determine the impact of csPC definitions on diagnostic performance of ADC and PI-RADSv2.We retrospectively identified treatment-naïve pathology-proven peripheral (...) zone PC patients who underwent 3T prostate MRI, using high b-value diffusion-weighted imaging from 2011 to 2015. Using 3D slicer, areas of suspected tumor (T) and normal tissue (N) on ADC (b = 0, 1400) were outlined volumetrically. Mean ADCT, mean ADCN, ADCratio (ADCT/ADCN) were calculated. PI-RADSv2 was assigned. Three csPC definitions were used: (A) Gleason score (GS) ≥ 4 + 3; (B) GS ≥ 3 + 4; (C) MRI-based tumor volume >0.5 cc. Performances of ADC parameters and PI-RADSv2 in identifying csPC were
Quality of Life During Treatment With Chemohormonal Therapy: Analysis of E3805 Chemohormonal Androgen Ablation Randomized Trial in ProstateCancer Purpose Chemohormonal therapy with docetaxel and androgen deprivation therapy (ADT+D) for metastatic hormone-sensitive prostatecancer improves overall survival as compared with androgen deprivation therapy (ADT) alone. We compared the quality of life (QOL) between patients with metastatic hormone-sensitive prostatecancer who were treated with ADT+D (...) and those who were treated with ADT alone. Methods Men were randomly assigned to ADT+ D (six cycles) or to ADT alone. QOL was assessed by Functional Assessment of Cancer Therapy-Prostate (FACT-P), FACT-Taxane, Functional Assessment of Chronic Illness Therapy-Fatigue, and the Brief Pain Inventory at baseline and at 3, 6, 9, and 12 months. The Wilcoxon signed rank test was used to examine changes over time. Mixed-effect models compared the QOL between arms at each time point. Results Seven hundred ninety
Docetaxel Versus Surveillance After Radical Prostatectomy for High-risk ProstateCancer: Results from the Prospective Randomised, Open-label Phase 3 Scandinavian ProstateCancer Group 12 Trial Adjuvant chemotherapy is standard treatment for other solid tumours, but to date has not proven effective in prostate cancer.o evaluate whether six cycles of docetaxel alone improve biochemical disease-free survival after radical prostatectomy for high-risk prostate cancer.Open-label, randomised (...) of 116 serious adverse events were recorded in Arm A and 41 in Arm B with no treatment-related deaths. Not all patients received docetaxel by protocol. The endpoint is biochemical progression and some patients received radiation treatment before the endpoint.Docetaxel without hormonal therapy did not significantly improve biochemical disease-free survival after radical prostatectomy.In this randomised trial, we tested whether chemotherapy after surgery for high-risk prostatecancer decreases the risk
-4N0M0 prostatecancer (median follow-up 48.9 and 25.0 mo, respectively), and genomic data for 4960 patients from the Decipher Genomic Resource Information Database. Data were collected for 2004-2017.Multivariable Fine-Gray and Cox regressions were used to analyze prostatecancer-specific mortality (PCSM) and all-cause mortality, respectively.For Gleason 8-10 disease, using PSA 4.1-10.0ng/ml (n=38 719) as referent, the distribution of PCSM by PSA was U-shaped, with an adjusted hazard ratio (AHR (...) Clinical and Genomic Characterization of Low-Prostate-specific Antigen, High-grade ProstateCancer The consequences of low prostate-specific antigen (PSA) in high-grade (Gleason 8-10) prostatecancer are unknown.To evaluate the clinical implications and genomic features of low-PSA, high-grade disease.This was a retrospective study of clinical data for 494 793 patients from the National Cancer Data Base and 136 113 patients from the Surveillance, Epidemiology, and End Results program with cT1